Peptides and therapies commonly used to extend lifespan.
Just because a peptide is commonly offered at longevity clinics doesn't mean it's been shown to work. GLP-1 peptide drugs like semaglutide have real outcome trials showing fewer heart attacks and deaths in people with obesity or diabetes — the strongest evidence in this category, even though they're prescribed for weight and metabolic disease rather than marketed as anti-ageing. Growth-hormone-releasing peptides raise hormone levels but come with a genuine cancer-risk concern and no lifespan evidence. BPC-157 and NAD+ infusions are popular in longevity clinics with essentially no human trials behind their claims. Stacking several unapproved peptides together adds unknowns rather than benefits.
Being commonly used in longevity clinics is a poor proxy for evidence, and this ranking separates the two. GLP-1 receptor agonist peptides (semaglutide, tirzepatide and related drugs) rank first, because randomised outcome trials show reduced cardiovascular events and death in people with obesity or type 2 diabetes, giving this category the strongest human evidence of any peptide commonly discussed in longevity circles, even though it is prescribed for weight and metabolic disease rather than marketed as anti-ageing. Growth-hormone-releasing peptides (sermorelin, ipamorelin, CJC-1295 and similar) rank second from the bottom of a much shorter positive list, because while they reliably raise growth hormone and IGF-1 levels, human trials link elevated IGF-1 in adulthood to increased, not decreased, certain cancer risks, and no trial shows these peptides extend human lifespan. BPC-157 and similar repair-marketed peptides rank near the bottom, commonly used for injury recovery claims with essentially no human trials — most evidence is from animal studies, and it remains unapproved for human use in most jurisdictions. NAD+ infusion therapy ranks similarly low, popular in longevity clinics with no randomised trials demonstrating a lifespan or major health outcome benefit in humans, only mechanistic and animal data. 'Longevity peptide stacks' combining several unapproved peptides rank lowest, compounding the lack of evidence for each individual component with unknown interaction effects and inconsistent sourcing quality, since most are not manufactured under pharmaceutical-grade regulatory oversight.
- Common use in longevity clinics does not correlate with strength of human evidence.
- GLP-1 agonist peptides have the strongest outcome-trial evidence, despite not being marketed primarily as anti-ageing.
- Growth-hormone-releasing peptides carry a specific cancer-risk concern from elevated IGF-1, not just an absence of lifespan evidence.
- BPC-157 and NAD+ infusions are popular and have essentially no human trial evidence for their marketed claims.
- Combining multiple unapproved peptides compounds uncertainty rather than compounding benefit.
Peptides and therapies ranked by human evidence
Ranked on: the strength of human randomised trial evidence for the specific claim made, and known safety data.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | GLP-1 receptor agonist peptides (semaglutide, tirzepatide and related) | The strongest human outcome-trial evidence in this category | GRADE AEstablished |
| 2 | Growth-hormone-releasing peptides (sermorelin, ipamorelin, CJC-1295 and similar) | Reliably raises hormone levels; a specific cancer-risk concern, no lifespan evidence | GRADE CEarly |
| 3 | BPC-157 and similar 'repair' peptides | Commonly used for injury claims with essentially no human trials | GRADE DInsufficient or unsafe |
| 4 | NAD+ infusion therapy | Popular in longevity clinics; no randomised human outcome trials | GRADE DInsufficient or unsafe |
| 5 | 'Longevity peptide stacks' combining multiple unapproved peptides | Compounds the lack of evidence rather than compounding benefit | GRADE DInsufficient or unsafe |
- 01
GLP-1 receptor agonist peptides (semaglutide, tirzepatide and related)
GRADE AEstablishedThe strongest human outcome-trial evidence in this categoryRandomised controlled trials show reduced cardiovascular events and death in people with obesity or type 2 diabetes taking these prescription peptide drugs, giving this class outcome evidence that essentially no other peptide discussed in longevity circles has, despite being prescribed for metabolic disease rather than marketed as anti-ageing.
- 02
Growth-hormone-releasing peptides (sermorelin, ipamorelin, CJC-1295 and similar)
GRADE CEarlyReliably raises hormone levels; a specific cancer-risk concern, no lifespan evidenceThese peptides reliably increase growth hormone and IGF-1 levels, but human epidemiological evidence links elevated adult IGF-1 to increased risk of certain cancers, and no trial demonstrates these peptides extend human lifespan or improve major health outcomes, making the risk-benefit picture concerning rather than merely unproven.
- 03
BPC-157 and similar 'repair' peptides
GRADE DInsufficient or unsafeCommonly used for injury claims with essentially no human trialsMarketed heavily for tissue repair and recovery, with most supporting evidence coming from animal studies rather than human trials. It remains unapproved for human use in most jurisdictions, and sourcing quality from compounding sources varies considerably outside pharmaceutical manufacturing oversight.
- 04
NAD+ infusion therapy
GRADE DInsufficient or unsafePopular in longevity clinics; no randomised human outcome trialsWidely offered as an anti-ageing infusion based on NAD+'s role in cellular metabolism, with no randomised trials demonstrating a lifespan or major health outcome benefit in humans — the supporting evidence is mechanistic and from animal studies, a considerably weaker basis than the marketing implies.
- 05
'Longevity peptide stacks' combining multiple unapproved peptides
GRADE DInsufficient or unsafeCompounds the lack of evidence rather than compounding benefitCombining several peptides, each individually lacking human trial evidence for the claims made, adds unknown interaction effects to the existing uncertainty about each component, along with the sourcing and quality-control concerns that apply to unapproved compounded peptides generally.
Why 'commonly used' does not mean 'well evidenced' here
Common clinic use versus trial evidence
| Peptide/therapy | How commonly offered in longevity clinics | Human trial evidence for the marketed claim |
|---|---|---|
| GLP-1 agonist peptides | Increasingly common, often for weight loss rather than anti-ageing framing | Strong — randomised outcome trials |
| Growth-hormone-releasing peptides | Very common in anti-ageing clinics | None for lifespan; cancer-risk signal from elevated IGF-1 |
| BPC-157 | Very common for 'repair' and recovery claims | Essentially none in humans |
| NAD+ infusions | Very common as a standalone anti-ageing offering | None for lifespan or major outcomes |
| Multi-peptide stacks | Common as a premium clinic offering | None — compounds the gaps in each component |
Frequently asked questions
What peptides and therapies are commonly used to extend lifespan?
Commonly offered options include GLP-1 receptor agonist peptides, growth-hormone-releasing peptides, BPC-157, NAD+ infusion therapy, and multi-peptide 'stacks'. Ranked on actual human trial evidence, only GLP-1 agonist peptides have randomised outcome trials showing reduced cardiovascular events and death; the rest have little to no human evidence for the lifespan or anti-ageing claims made about them.
Do GLP-1 drugs like semaglutide actually extend lifespan?
Randomised outcome trials show reduced cardiovascular events and death in people with obesity or type 2 diabetes taking these drugs, which is meaningfully stronger evidence than exists for any other peptide commonly discussed in longevity circles, though they are prescribed for a specific metabolic indication rather than marketed generally as anti-ageing.
Are growth-hormone-releasing peptides safe for longevity?
They reliably raise growth hormone and IGF-1 levels, and human epidemiological evidence links elevated adult IGF-1 to increased risk of certain cancers, while no trial shows these peptides extend lifespan. This combination of a documented risk concern and absent benefit evidence is a meaningfully different situation from simply being unproven.
Is BPC-157 proven to help with recovery or longevity?
Most supporting evidence is from animal studies rather than human trials, it remains unapproved for human use in most jurisdictions, and sourcing quality varies considerably since it is typically obtained through compounding rather than pharmaceutical manufacturing with standard regulatory oversight.
Does NAD+ infusion therapy have human evidence for anti-aging effects?
No randomised human trials demonstrate a lifespan or major health outcome benefit from NAD+ infusions; the supporting rationale comes from NAD+'s role in cellular metabolism studied mechanistically and in animal models, which is a considerably weaker evidence base than the marketing around these infusions typically implies.
Is combining multiple peptides in a 'stack' better than using one?
There is no evidence for this. Combining several peptides, each individually lacking human trial evidence for the claims made about it, adds unknown interaction effects on top of the existing uncertainty about each individual component, rather than producing a demonstrated combined benefit.
Keep reading
- Longevity peptides
The full peptide-by-peptide evidence grading.
- How to choose the best longevity peptides safely?
Safety and sourcing considerations in depth.
- Which longevity peptides are best for energy and recovery?
A related ranking focused on the energy and recovery claim specifically.
- Free stack check
Check any peptide against your current medicines.
More in Peptides
- Which longevity peptides are best for energy and recovery?
BPC-157, TB-500, MOTS-c, CJC-1295, ipamorelin, sermorelin, tesamorelin — ranked on human trials for energy and recovery. Most have none. Here is what actually exists.
- What are the safest and best longevity peptides?
Longevity peptides ranked on safety and human evidence together: tesamorelin, PT-141, sermorelin, GHK-Cu, semax and selank, DSIP, then the unregulated injectables — BPC-157, TB-500, MOTS-c, CJC-1295/ipamorelin, epitalon, AOD-9604, melanotan II — with the regulatory status of each.
- Best longevity peptides for anti-aging and cellular repair.
Longevity peptides ranked on their anti-ageing and cellular-repair claims: what each is supposed to repair, what the human evidence shows, and why GHK-Cu on skin outranks every injectable — tesamorelin, BPC-157, TB-500, epitalon, MOTS-c, thymosin alpha-1 and more.
- Which longevity peptides work best for lifespan extension?
Which longevity peptides have any evidence for extending lifespan, ranked honestly: none in humans; the animal data behind epitalon, MOTS-c, SS-31, humanin and the GH-axis peptides; and why the best-evidenced lifespan interventions are not peptides.
- Best longevity peptides for beginners to start with.
Longevity peptides for beginners, ranked on what a first peptide should be — lawful, prescribed, human-studied, low-risk: topical GHK-Cu, then approved peptides via a prescriber, then the grey-market injectables that beginners are usually sold first and should try last, if at all.
- What are the top doctor-recommended longevity peptides?
Doctor-recommended longevity peptides ranked by what the recommendation rests on: guideline-backed prescribing (tesamorelin, bremelanotide), evidence-informed off-label use (sermorelin), and the clinic-menu peptides — BPC-157, TB-500, CJC-1295/ipamorelin — that are recommended commercially and cannot be lawfully compounded.